Table 1.
Characteristics and clinical progression of our patient.
| Variable | |
|---|---|
| Age (years) | 46 |
| Anthropometric data | Weight: 86 kg, height: 163 cm, BMI: 32.40 kg/m2 |
| Vital signs at admission | HR: 115 bpm, RR: 24 bpm, BP: 130/70, temp.: 39°C, O2 sat.: 85% |
| Family history | Mother: SAH and DM2 |
| Medical history | DM2 (since 2004), SAH (since 2019) |
| Toxic substance use | Alcohol (once per month), tobacco (social smoker, once per week) |
| Long-term treatment before admission | Insulin (insulin glargine + lixisenatide) 22 IU/day, furosemide 40 mg/24 h, amlodipine 5 mg/24 h, pravastatin 20 mg/24 h, linagliptin/metformin 2.5/850 mg/8 h |
| Time from symptom onset to PRES onset (days) | 22 |
| MAP (range) | 69-130 mm Hg |
| Laboratory analyses | Admission | Critical phase | Discharge |
|---|---|---|---|
| Leukocyte count (cells/mm3) | 9.10 | 18.8 | 9.3 |
| Platelet count (count/mm3) | 207 000 | 657 000 | 203 000 |
| Creatinine (mg/dL) | 2.50 | 3.71 | 1.09 |
| CRP (mg/dL) | 20.56 | 20.56 | 1.13 |
| ESR (mm/h) | 101 | 104 | 22 |
| Ferritin (ng/mL) | 435.8 | 1581 | 643 |
| D-dimer (ng/mL) | 500.54 | 6161 | 651 |
BMI: body mass index; BP: blood pressure; CRP: C-reactive protein; DM2: diabetes mellitus type 2; ESR: erythrocyte sedimentation rate; HR: heart rate; MAP: mean arterial pressure; O2 sat.: oxygen saturation; PRES: posterior reversible encephalopathy syndrome; RR: respiratory rate; SAH: systemic arterial hypertension; temp.: body temperature.